| 摘要 |
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to oxazolopyrimidine compounds of formula, wherein A is specified in O or S; X is specified in (C-C)-alkanediyl, (C-C)-alkenediyl and (C-C)-alkanediyl-oxy, wherein an oxygen atom of (C-C)-alkanediyl-oxy group is bound to the group R; Y represents a 4-7-merous saturated monocyclic heterocycle; Rrepresents hydrogen; Ris specified in phenylene, which is optionally substituted by one or two identical or different substitutes R; Ris specified in phenylene and thiazole, wherein a ring residue is optionally substituted by identical or different substitutes Rat one or two carbon atoms of the ring; Ris specified in halogen and (C-C)-alkyl-, which is optionally substituted by 1-3 fluorine atoms; Ris specified in halogen, (C-C)-alkyl and (C-C)-alkyloxy. The invention also refers to a method for producing the compounds of formula I and to a pharmaceutical composition applicable for activating EDG-1 receptor.EFFECT: compounds of formula I applicable for activating EDG-1 receptor and for treating disturbed wound healing and diabetic foot.18 cl, 2 tbl, 37 ex |
